# Intranasal Administration of Dodecyl Creatine Ester (CBT101) in Healthy Male Subjects

> **NCT07050316** · PHASE1 · COMPLETED · sponsor: **Ceres Brain Therapeutics** · enrollment: 48 (actual)

## Conditions studied

- Neurologic Diseases, General

## Interventions

- **DRUG:** CBT101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07050316
- **Lead sponsor:** Ceres Brain Therapeutics
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-14
- **Primary completion:** 2025-09-26
- **Final completion:** 2025-09-26
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07050316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07050316, "Intranasal Administration of Dodecyl Creatine Ester (CBT101) in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07050316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*